Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients

Inclusion Criteria:

Pathologic confirmation of prostate cancer.
Any T-stage.

By imaging or clinical criteria, any patient with disease staging of N0/N1 and M0/M1.

Patients with metastatic disease are encouraged to participate.
Any Gleason Score will be eligible.

Androgen deprivation therapy (ADT) is at the discretion of the treating physician, but must be declared as none, short-term, long-term, or extended prior to enrollment. The length is calculated from the LHRH (agonist injection). If ADT is planned (based on treating physician preference), the following restrictions apply:

Short term ADT is defined as ≤ 7 months;
Long term ADT is defined as > 7 months and ≤ 36 months;
Extended ADT is defined as >36 months (e.g., M1 patients).
Prostate-specific antigen (PSA) ≤100 ng/mL within (+/-) 4 months of signing of consent. If PSA was above 100 and drops to <100 with antibiotics, this is acceptable for enrollment.
No previous pelvic radiotherapy.
The ability to understand and the willingness to sign a written informed consent document
Zubrod performance status ≤ 2 (Karnofsky or ECOG performance status may be used to estimate Zubrod):
Age ≥ 30 at signing of consent.
Subjects must be planned to receive radiation therapy or to undergo prostatectomy.
Subjects treated primarily with RT are recommended to have had an MUFgBx prior to radiation treatment.